J. Patrick van der Voorn

About

J. Patrick van der Voorn is a leading clinical researcher in nuclear medicine and urologic oncology, whose work has fundamentally advanced the use of PSMA PET/CT imaging for prostate cancer management. His primary research focuses on improving the accuracy of prostate cancer staging and guiding treatment decisions through molecular imaging. Dr. van der Voorn’s major contributions include the landmark SALT trial (106 citations), which demonstrated the high sensitivity of 18F-DCFPyL PSMA PET/CT for detecting pelvic lymph-node metastases prior to extended lymph-node dissection in primary prostate cancer. This work has reshaped preoperative staging protocols, reducing the need for invasive surgical staging. Additionally, his DeTeCT trial (47 citations) explored the feasibility of using PSMA PET/CT to guide targeted biopsies of the prostate, correlating imaging findings with final histopathology after radical prostatectomy. This research opens the door for more precise, image-guided tissue sampling. With over 150 combined citations for these two pivotal studies alone, Dr. van der Voorn’s work is widely recognized for its direct clinical impact, helping to personalize treatment for patients with prostate cancer and setting new standards for non-invasive staging.

Research Focus

Key Achievements

Top Papers

1. 1
   Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -

   106 citations · 2020
2. 2
   Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial

   47 citations · 2020

Key Collaborators

Contact & Links